Polaris Pharmaceuticals
Nicole DeFord, MA, is an experienced clinical research professional with a robust background in oncology and multi-departmental clinical investigations. Currently serving as an Associate Clinical Trial Manager at Polaris Pharmaceuticals since June 2021, Nicole leads the start-up of a Phase 1 cancer trial and conducts monitoring for Phase 1 and 2 oncology trials. Prior to this, Nicole held the position of Lead Clinical Research Associate at Odyssey Systems, overseeing and supporting research activities at the San Diego Naval Medical Center across various surgical departments. Additional experience includes roles at General Dynamics Information Technology, The Henry M. Jackson Foundation, and San Diego VA Health Care System, focusing on clinical trials and patient treatment in diverse medical fields. Nicole also contributed to academia as an Adjunct Professor and Graduate Teaching Associate at San Diego State University. Nicole holds a Master’s Degree in Experimental Psychology and a Bachelor’s Degree in Psychology, both from San Diego State University.
This person is not in any teams
Polaris Pharmaceuticals
Polaris Group, a privately held multinational biopharmaceutical drug company, specializes in the research and development of protein drugs to treat cancer and other debilitating diseases in humans. Polaris' lead project is ADI-PEG 20, a biotherapeutic agent that is in advanced clinical development for the treatment of hepatocellular carcinoma and metastatic melanoma. Polaris is collaborating with EnzymeRx in the development of Uricase-PEG 20 for the treatment of gout, tumor lysis syndrome, and other diseases related to hyperuricemia. Polaris is also researching and developing other biotherapeutic agents and has a small molecule drug program. The latter utilizes a rational structure-based approach for the design of novel compounds that inhibit the biological function of cancer-related protein targets.